glycopyrrolate
glycopyrrolate: sourced relationships with 1 company · 4 clinical trials tracked · 1 FDA decision.
glycopyrrolate evidence translation
What we can confirm
1 FDA record · 4 tracked trials
What it means
What to watch
Prepared research question
How could glycopyrrolate → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Novartis AG (NVS) Reported 2015-10-29 · Current development: unknownSource | Approved |
| Novartis AG (NVS) Reported 2015-10-29 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (4)
A Phase II, Randomized, Double-Blind, Cross-Over Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-Glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
Primary endpoint: Ensifentrine single dose area under the curve from time 0 to time t (AUC0-t)
A Phase IIb, Randomized, Double-blind, Placebo- Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ensifentrine-glycopyrrolate Fixed-dose Combination at Two Dose Levels Compared to Glycopyrrolate or Ensifentrine Monotherapy in Subjects With COPD
Primary endpoint: Change From Baseline in Average Forced Expiry Volume in 1 Second (FEV1) Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h)
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
Primary endpoint: Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1)
A Double-blind, Randomized, Parallel Group Study to Compare Rocuronium Reversal With Sugammadex (Bridion®) Versus Neostigmine/Glycopyrrolate and the Incidence of Urinary Retention After Elective Ambulatory Posterior Lumbar Laminectomy
Primary endpoint: Number of Participants Who Experienced Urinary Retention
Frequently asked questions
Which companies have sourced relationships with glycopyrrolate?
glycopyrrolate has dated SEC/FDA relationship records for Novartis AG.
How many clinical trials involve glycopyrrolate?
BioSniper tracks 4 clinical trials involving glycopyrrolate.
What is glycopyrrolate's latest FDA decision?
The most recent tracked FDA decision for glycopyrrolate is Approval, dated October 29, 2015.